Novel approaches towards conquering hepatitis B virus infection

Table 1 Anti-HBV nucleoside/nucleotide analogues under development

Phase	Drugs	Company
Phase III	Emtricitabine (FTC)	Gilead (California, USA)
	Tenofovir DF	Gilead (California, USA)
	Telbivudine (L-dT)	Idenix (Massachusetts, USA)
	Clevudine (L-FMAU)	Gilead/Triangle (California, USA)
Phase II	Elvucitabine (β-L-Fd4C)	Achillion (Connecticut, USA)
	Valtorcitabine (val-L-dC)	Idenix (Massachusetts, USA)
	Amdoxovir (DAPD)	Triangle (California, USA)
	Racivir [(+/-)-FTC]	Pharmasset (New Jersey, USA)
	LB80380	LG Life Sciences (Seoul, Korea)
Phase I	Alamifovir (purine nucleoside analogue)	Lilly/Mitsubishi (Indiana, USA/Osaka, Japan)
	MIV 210 (FLG prodrug)	Medivir/GSK (Huddinge, Sweden/Brentford, UK)
	Hepavir B (PMEA prodrug)	Ribapharm (California, USA)
Pre-clinical	β-L-FddC	Biochem/GSK (Sante-Foy, Canada/Brentford, UK)
	6- [2- (phosphonomethoxy) alkoxy]-2, 4-diaminopyrimidines	Rega Institute for Medical Research, K.U.Leuven (Leuven, Belgium)
	2-benzenesulfonylalkyl-5-substituted-sulfanyl-[1, 3, 4]-oxadiazoles	National University of Singapore (Singapore)